Company profile
ADMA Biologics, Inc.
NASDAQ: ADMA · Healthcare · Biotechnology
#209 of 1,418 Healthcare companies by revenue65th-percentile growth
EA Score
85AFH 91DQ 85GM 71SS 76
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ listing tenure, revenue growth (YoY)
Methodology →Revenue TTM
$509.9M
Rev growth YoY (TTM)
+11.0%
Net income (FY)
$146.9M
Employees
647
as of 2026-08-09
Market cap
$2.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$510.2M$510.2M2025
Net income$146.9M$146.9M2025
Operating income$191.4M$191.4M2025
Total assets$624.2M$624.2M2025
Liabilities$146.9M$146.9M2025
Equity$477.3M$477.3M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ADMA Biologics, Inc.’s revenue?
ADMA Biologics, Inc. booked $510.2M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a 28.8% net margin.
Peers · Healthcare
Mirum Pharmaceuticals, Inc.64CVeracyte, Inc.82B+Inotiv, Inc.63CGlaukos Corporation71BThe Oncology Institute, Inc.52DBridgeBio Pharma, Inc.53DNeighbors
Bergen →Key facts
CEOAdam S. Grossman
SectorHealthcare
IndustryBiotechnology
HeadquartersRamsey, NJ
ExchangeNASDAQ: ADMA
Employees647
IPO date2013-10-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.